secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2026-07-15T12:30:36+00:00
Accession:  0001493152-26-033289
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma reports zero Grade 3+ toxicities from ENV-105 in Phase 1 NSCLC trial
--------------------------------------------------------------------------------

- Zero Grade 3+ toxicities from ENV-105 in 13 patients with advanced EGFR-mutated NSCLC.
- ENV-105 (carotuximab) combined with osimertinib (Tagrisso) shows clean safety profile.
- Targets $10B drug resistance market; no FDA-approved agent to reverse osimertinib resistance.
- Phase 1 trial ongoing; safety data supports continued development toward efficacy readout.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226033289/0001493152-26-033289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226033289/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-033289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer